October 3rd: Dan Ollendorf, PhD, ICER’s Chief Scientific Officer, will participate in a stakeholder meeting on Promoting Uptake of Core Outcome Sets in Clinical Research, hosted by the Center for Medical Technology Policy.
October 5th: Bill Dreitlein, PharmD, ICER’s Director of Pharmaceutical Policy, will speak at a Health Technology Assessment Workshop at the Cell & Gene Meeting on the Mesa in La Jolla, CA.
October 9th-10th: Steven Pearson, MD, MSc, ICER’s president, will participate in the Laguna Biotech CEO conference in Laguna Beach, CA.
October 11th: Dan will present at Cardiology Grand Rounds at Massachusetts General Hospital in Boston, MA.
October 17th-20th: Dan will speak at the Market Access for Cell and Gene Therapies conference held in London.
October 19th: Sarah Emond, MPP, ICER’s Executive VP and Chief Operating Officer, will present to the National Business Group on Health’s National Committee on Pharmacy Benefits and Specialty Medicine.
October 26th: Steve will participate in the annual Galien Forum in New York, NY, speaking on a panel session titled “Drug Pricing and Access in the Trump Administration: Consensus or Confrontation?”
October 31st: Dan will participate in a meeting of the Eastern Medicaid Pharmacy Administrators Association in Newport, RI.
October 2nd: Draft Evidence Report for Tardive Dyskinesia
October 2nd- October 30th: Public comment period
October 4th: Evidence Report for Chronic Low Back and Neck Pain